pipeline

Three programs in phase II

Our research and development is focused on applying excellent science to discover and develop potential new synthetic DNA vaccines with the goal of creating first-in-class or best-in-class therapeutics and/or preventives.

Cancer
Infectious Diseases
Internally Funded
Partner Funded

Disease	Vaccine Program	Antigen	Partner/ Funding/ Sponsor
Cervical dysplasia HPV Type 16/18 Info	VGX-3100	E6, E7		Therapeutic Info: Milestone: Enrolling international phase II study; aiming for results in the first quarter of 2014 Highlight: Phase I trial shows vaccine produces "killer T-cells" that kill cervical dysplasia cells
Leukemia CML & AML	WT1 Vaccine	WT1	Owned/funded by U. of Southampton/ LLR and CRUK* (Inovio electroporation)	Therapeutic Info: Milestone: Additional phase II results 2013 Highlight: Preclinical data showed strong induction of antigen-specific CD8+ T cells; killed human tumor cells expressing WT1.
Prostate cancer Info	INO-5150	PSA, PSMA		Therapeutic Info: Milestone: Aiming for phase I study launch in 2013 Highlight: Successful large animal results reinforce potential utility of Inovio's DNA vaccine approach for treating cancers
Hepatitis C Genotype 1a & 1b Info	INO-8000	NS3/4A, NS4B, NS5A	VGX International, Inc.	Therapeutic Info: Milestone: Initiate phase I/IIa in HCV infected individuals in the fourth quarter of 2013 Highlight: Rhesus macaques mounted strong HCV-specific T cell immune responses strikingly similar to those reported in patients who have cleared the virus on their own.
Genotype 1a Info	ChronVac-C^®	NS3/4A	Owned by ChronTech (Inovio electroporation)	Therapeutic Info: Milestone: Phase II interim data expected in the first quarter of 2013 Highlight: Phase I results demonstrated a complete and rapid viral response in 83% of participants
HIV Clade B Info	PENNVAX^®-B	gag, pol, env	HIV Vaccine Trials Network	Preventive & Therapeutic Info: Milestone: Final phase I data expected in the first half of 2013 Highlight: Significant vaccine-specific T-cell responses observed in 89% of phase I subjects
Clades A, C, D Info	PENNVAX^®-G	env, gag	USMHRP/NIAID	Preventive & Therapeutic Info: Milestone: Complete enrollment at three study centers except the U.S. Highlight: PENNVAX®-G plus MVA boost achieves 100% antigen-specific T-cell immune responses and safety with interim data
Clades A, C Info	PENNVAX^®-GP	gag, pol, env	NIH/NIAID	Preventive & Therapeutic Info: Milestone: Initiate phase I study in 2013 Highlight: PENNVAX-GP generated robust antigen-specific T-cell responses and protection from the virus in pre-clinical studies
Influenza - UniversalPandemic Info	VGX-3400X	HA, NA, NP		Preventive Info: Milestone: Phase I completed Highlight: Demonstrates immune responses against six unmatched H5N1 strains
Seasonal Info	Various	HA	NIH Director's Office Transformative Research Award	Preventive Info: Milestone: Interim results reported; additional results from a higher dose group expected in 2013 Highlight: Vaccine shows protective immune responses in humans against the nine key H1N1 flu strains of past 100 years, including 1918 pandemic flu
Malaria Info	Various	Various	MVI/PATH	Preventive Info: Milestone: Initiate phase I/IIa study in 2014

* Leukaemia and Lymphoma Research and Cancer Research UK

Page 'Breadcrumb' Navigation